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therapy combined with diuretics
Abstract
Introduction. Management of edema due to advanced disease is seldom recognized in palliative care. The 
purpose of this pilot study was to assess the effectiveness and tolerance of conservative edema therapy.
Material and methods. Prospective analysis of limb volumes, edema symptom burden and quality of life 
(QoL) in 119 patients diagnosed with edema was performed. Eighteen patients in their last days of life 
complaining of edema were treated by limb elevation, supportive (palliative) bandaging, manual lymphatic 
drainage, Kinesio Taping and/or controlled subcutaneous needle drainage. Forty-six with longer prognosis 
were treated by one-week multilayer short-stretch limb bandaging and then re-evaluated. Twenty-eight 
of them with venous congestion resistant to previously given diuretics received additionally furosemide 
infusion in hypertonic saline. Subgroups analysis of the patients with diuretic therapy and primary lym-
phatic congestion was performed.
Results. Within 46 patients re-evaluated the reduction of limb volume was accompanied by a decrease 
of edema symptom intensity and an improvement of QoL. Subgroup analysis revealed both volume and 
symptomatic improvement, equally effective in cases with suspected lymphatic congestion or when di-
uretics were added.
Conclusion. Edema of advanced disease irrespective of the lymphatic component can be effectively 
managed conservatively with short–stretch limb bandaging. In cases resistant to oral diuretic fluid over-
load, parenteral hypersaline furosemide addition to the compression may be the safe therapeutic option 
enhancing treatment tolerance.
Palliat Med Pract 2019; 13, 2: 51–56
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Introduction
Edema at the end of life population is a common 
harmful symptom, still seldom recognized. Despite 
typical presentation in the literature as lymphedema, 
it generally has a combined etiology (e.g. increased 
capillary hydrostatic, decreased plasma oncotic pres-
sures, increased capillary permeability and lymphatic 
obstruction) [1]. The management engages the whole 
palliative multidisciplinary team [2]. Some case studies 
described various types of edema management. The 
most often recommended physiotherapeutic manage-
ment strategies are characterized by poor tolerance 
[3]. The purpose of this paper, following recently 
published cross sectional study [4], was to assess the 
effectiveness of the intensive conservative manage-
ment including short stretch compression bandaging 
broadened by additional diuretic treatment in cases 
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of general fluid congestion, provided within the hos-
pice setting. Subgroups analysis of suspected primary 
lymphatic congestion origin edemas and the patients 
with diuretic addition was performed.
Material and methods
A prospective analysis of all patients with visible, 
spontaneously irreversible, chronic edema admitted to 
the free-standing hospice was performed. On admis-
sion, the edema localization and limb volumes were 
calculated by circumferential tape measurements. Ad-
ditionally typically observed with edema sensations 
and overall wellbeing impairment (measured by the 
5-item Likert scale: none, little, moderate, severe, very 
severe) were scored. The quality of life (QoL) accord-
ing to Edmonton Symptom Assessment System-Core 
(ESAS-C) [5] was also monitored. ESAS-C is a shortened 
ESAS version designed for patients in their last days 
of life, with an improved completion rate. It equals 
the sum of five core symptom intensity measured on 
a numeric rating scale (NRS): pain, dyspnea, nausea, 
audible chest secretions and agitation (scores of each 
symptom range from 0 — the best to 10 — the worst, 
thus the total ESAS-C scores range from 0 to 50).
In those cases where the edema was noticed by 
the patients and caused discomfort, the 2–3 layers 
of short-stretch bandage compression (8 and 10 cm 
width, Rosidal K, Lohmann & Rauscher, Germany) were 
applied by two skilled physiotherapists. Additionally, 
in patients with signs of systemic and/or pulmonary 
venous congestion, and when edema was resistant 
to previously given diuretics, parenteral furosemide 
(mean dose 60 mg, range 40–100 mg) was given over 
an hour in hypersaline intravenous infusion (30 mL 
10% NaCl in 250 mL normal saline) concurrently with 
the compression, once daily. Routine daily clinical 
bedside physical evaluation of fluid congestion was 
performed. Later, after 5–7 days of such therapy, limb 
volumes, symptom intensity, well-being and QoL was 
re-evaluated. The study protocol was approved by the 
Local Ethics Committee.
Statistical analysis
Means with standard deviations (SD) of normally 
distributed continuous variables in one sample (be-
fore and after intervention) were compared using 
paired t-test. Wilcoxon signed rank test was used to 
compare medians with interquartile ranges (IQR) of 
non-normally distributed continuous or ordinal data 
in one sample. The association between the pres-
ence of pathognomic for the presence of lymphede-
ma Stemmer Sign (inability to ‚tent’ the skin of the 
lymphedematous interdigital skin fold) and positive 
history of lymphatic impairment was calculated using 
McNemar’s test. Comparison between subgroups was 
done using the Mann-Whitney U test (when compar-
ing two variables) or the Kruskal-Wallis test (in four 
subgroups). A P the value of 0.05 was considered 
statistically significant. Data analysis was performed 
through the R software environment for statistical 
computing and graphics software v. 3.5.0 [6].
Results
Among 119 patients (58.8% females) who were 
diagnosed on admission with edema the majority 
had advanced cancer in Gold Standard Framework 
(GSF) [7] stage C and with bilateral edema, stage 
2 according to the International Society of Lym-
phology. In 33 patients (27.7%) the edema was the 
main problem on admission. The mean duration 
of hospice care was 11 days; 106 patients (89.1%) 
eventually died. The leading causes of edema seen 
were chronic immobilization due to asthenia (95; 
79.8%) and edema precipitating pharmacotherapy 
provided (70; 58.8%). Fifty-six (91.8%) of 61 pa-
tients clinically suspected of lymphedema had positive 
Stemmer sign [8], which contrasted to 11 (19.0%) 
cases within the group who were not suspected of 
lymphatic congestion (Odds Ratio 0.36; Confidence 
Interval 0.08–1.22; p = 0.12). Only 5 persons (4.2%) 
received edema physiotherapy before the admission. 
Forty-one cases of edema (34.5%) were not treated 
at the hospice, as this symptom was unnoticeable for 
the patients on examination (not being the source of 
suffering). Eighteen patients in their last days of life 
complaining of edema were qualified to individual-
ly tapered supportive management: limb elevation, 
supportive (palliative) compression bandaging (CB), 
manual lymphatic drainage (MLD), Kinesio Taping or 
controlled subcutaneous needle drainage and were 
not systematically re-evaluated.
Forty-six patients (38.6%; 84 limbs in total), were 
managed by daily compression bandaging applied uni-
formly and re-evaluated. Eighteen patients (33 limbs) 
received diuretics additionally to compression. The 
edema with suspected concomitant lymphatic con-
gestion was more advanced on admission, but the 
effect achieved through the two types of manage-
ment appeared to be congruent (Table 1). Within all 
re-evaluated an excellent adherence to the prescribed 
treatment was seen: every patient fulfilled the strict 
scheduled 5–7 days management. There were no signs 
of additional venous fluid accumulation due to limb 
compression. All re-evaluated continued compression 
bandaging as needed (8 hours every 1–3 days) up to 
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the dying phase or hospice discharge — diuretic sub-
group with oral torsemide (range 2.5–10 mg a day).
The intensity of commonly seen edema symptoms 
and overall well-being impairment improved in a short 
time within the whole group of patients (Fig. 1).
The sum of edema sensations severity in all those 
treated decreased from 17 (IQR 11–20) to 7 (5–15); 
p  <  0.001). The median total ESAS-C score decreased 
from 25 to 16 (p = 0.002). The subgroup analysis re-
vealed symptomatic improvement in edema sensations 
Table 1. Limb volumes (L) and volume change within the managed group and subgroups
Group/ 
/Sub-
groups
Patients Limbs Mean (SD) limbs volume 
(L)
Mean (SD)/median (IQR) 
limbs volume change
p
n % n % On 
admission
After 5–7 
days
L % of initial 
volume
Total 46 100.0 84 100.0 6.66 (3.14) 5.48 (2.57) –1.18 (1.4) –16.6 (14.1) < 0.001*
LE 32 69.6 57 67.9 7.35 (3.21) 6.01 (2.58) –1.35 (1.54) –17.2 (13.9) < 0.001*
nLE 14 30.4 27 32.1 5.19 (2.43) 4.37 (2.20) –0,82 (0,95) –15.5 (14.7) < 0.001*
p = 0.001$ p = 0.3$
CB 28 60.9 51 60.7 7.18 (3.28) 5.93 (2.60) –1.25 (1.60) –15.5 (14.9) < 0.001*
CBD 18 39.1 33 39.3 5.85 (2.76) 4.78 (2.39) –1.07 (1.03) –18.4 (12.7) < 0.001*
p = 0.17$ p = 0.8$
LE + 
CBD
11 23.9 19 22.6 7.33 (2.54) 6.14 (2.16) –1.19 (1.19) 16.4 (12.8) < 0.001*
nLE + 
CBD
7 15.2 14 16.7 3.84 (1.50) 2.93 (1.11) –0.90 (0.77) 21.2 (12.5) < 0.001*
LE + CB 21 45.7 38 45.2 7.37 (3.53) 5.94 (2.79) –1.43 (1.70) 7.6 (14.6) < 0.001*
nLE + CB 7 15.2 13 15.5 6.64 (2.44) 5.91 (2.04) –0.76 (–1.22 to 
–0.42)
10.5 (–4.8 to 
–20.0)
0.02**
p = 0.07# p = 0.3#
LE — edema of lymphatic etiology; nLE — non-lymphatic etiology; CB — compression bandaging; CBD — compression bandaging and diuretics 
Significance within the group (*t-test; **Wilcoxon Signed Rank test); significance between subgroups ($Mann-Whitney U test; #Kruskal-Wallis test)
Figure 1. The percentage of the intensity of commonly seen edema symptoms and QoL impairment according to 
the Likert 5-item scale on admission (before) and after 5–7 days of the management within the group of 46 patients 
(Wilcoxon Signed Rank Test)
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and limb heaviness in every subgroup but analyzed 
symptom changes correlated neither with the edema 
etiology nor with the management intensity (Table 2)
Discussion
The typical feature seen on hospice admission 
was bilateral lower limbs mixed etiology disease in-
volvement, that confirmed previous observations [9]. 
Nearly two-thirds revealed late stages of edema which 
are more problematic to manage. The suspicion of 
lymphatic congestion being the primary cause of 
edema was made on the basis of a history of iatro-
genic oncological treatment. Positive Stemmer sign 
made diagnosis more presumable but positive test in 
11 cases without a history of lymphatic damage indi-
cated secondary lymphatic insufficiency. Despite the 
presence of cancer in nearly all cases, non-lymphatic 
edema etiology (relative fluid overload, low plasma 
oncotic pressure, or/and elevated venous pressure) 
seemed to be of equal importance. In these situations, 
capillary filtration overwhelmed the lymph drainage 
for a significant period of time. The lymph transport 
which ensures the interstitial fluid drainage cannot 
be maintained indefinitely. At first, the increased 
lymphatic load prevails the lymphatic physiological 
outflow capacity, which leads to functional insufficien-
cy. This longer lasting process promotes inflammation, 
tissue fibrosis and lymphatic congestion — condition 
similar that is in lymphedema. In practice, most edema 
seen are compound of origin, and when untreated 
they consisted of both lymphatic congestive failure 
and high microvascular fluid filtration [10].
The drugs typically used to treat edema prior to 
palliative care were diuretics, however, they were in-
sufficient in this group, probably also due to lowered 
oncotic pressure in hypoalbuminemia [11]. This kind 
of therapy can be even counterproductive, as diuret-
ics diminish water and electrolytes in the edematous 
tissue, leaving cells and proteins, thus promoting 
earlier connective/fat formation. Clinicians should 
take into account the plethora of side effects of these 
drugs profoundly diminish the patient’s QoL. The 
primary aim of palliative care is to improve comfort 
measures, increasing/maintaining functional capacity 
and enhancing QoL, rather than to resolve the swelling 
completely. Therefore, any treatment that may be bur-
densome with minimal benefit should be avoided [12].
Various therapeutic modalities are proposed to 
palliative care patients with edema. The standard phys-
ical therapy for these patients is still being debated, 
as controlled studies are lacking. When life prognosis 
is short and edema quite stable, with low risk of fur-
ther progression limb elevation, MLD [13] or Kinesio 
Taping are preferred. In more advanced cases the trial 
of palliative CB or controlled subcutaneous needle 
drainage can be initiated [14]. Unfortunately, in this 
study, the effectiveness of these techniques could not 
be assessed due to high attrition rate (14 patients died 
within a week). A substantial number of palliative care 
patients can tolerate only these methods that may have 
a beneficial role in symptom or QoL improvement de-
spite an unproven value in edema reduction [15]. In pa-
tients with longer prognosis standard [16] or modified 
[3] programs of complex decongestive therapy (CDT) 
adapted to the patient’s reduced treatment tolerance 
should be considered [17]. Short-stretch CB seems 
to be the most reducing limb volume component of 
CDT as MLD may not be necessary for limb volume 
reduction [18]. It is characterized by high working 
and low resting pressures, well tolerated and safer in 
moderately impaired arterial circulation or in chron-
ic compensated heart failure [19]. However, careful 
consideration of the compression risk factors (further 
compromise arterial inflow or signs of additional ve-
nous fluid accumulation) should be monitored.
CB may not be well tolerated in palliative care 
population, thus in this trial, a combination of com-
pression with pharmacotherapy was considered when 
fluid congestion was diagnosed. Combining paren-
teral diuretics with limb compression was previously 
shown to be safe in the case series of 19 patients 
[20]. Stable levels of blood pressure, laboratory kidney 
profiles (potassium, sodium, creatinine clearance) and 
serum albumin were also seen. In the current study, 
any signs of increasing fluid congestion (e.g. jugular 
veins distension, ascites progression or new edema, in 
particular genital, onset) were not seen. The symptom 
profile and QoL improvement in diuretic subgroup 
were similar to patients without diuretics administra-
tion. Furosemide before the hospice admission usually 
administered orally failed to adequately control salt 
and water retention despite dose escalation [21]. 
One of the strategies for overcoming this resistance is 
adding hypertonic saline solution [22] that probably 
restore the effective arterial volume and improve neu-
rohormonal inhibition and renal hemodynamics [23]. 
However, possible short term risk factors of diuretics 
(e.g. acute renal insufficiency, electrolytes imbalance 
or thrombosis) should be also taken into account.
In this study the achieved positive effects in terms of 
limb volume reduction and decreasing edema symptom 
load which were visible regardless of the etiology of the 
disease or the diuretic addition. Reasonable patients’ 
compression tolerance in this study, despite initially 
visible fluid congestion, suggests the beneficial clinical 
effect of added furosemide in the hypersaline infusion. 
Questions remain about the optimal use of diuretics 
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(avoiding excessive treatment) to obtain efficient de-
congestion. In the hospice setting simple physical exam-
ination monitoring of the neck veins and blood pressure 
are valuable [21]. In addition, the serial measures of 
hematocrit levels, indicating for the adequacy of fluid 
refilling rate from the extravascular to the vascular 
compartment could be helpful [22]. Compression limb 
bandaging, in turn, added to diuretics may promote the 
compensation of an excessively fast vessel fluid with-
drawal. This small sample size and observational type 
of the study, limited to those who had been admitted 
to a single free-standing hospice, however, need to be 
validated in larger, randomized trials.
Conclusions
Edema in patients with advanced diseases is a po-
lietiology group of diseases, including lymphatic con-
gestion. It is a common source of suffering that can be 
effectively managed conservatively with short-stretch 
limb bandaging. In cases of edema in patients with 
resistance to oral diuretics fluid overload, parenteral 
hypersaline furosemide addition to the compression 
can facilitate this treatment tolerance and may be the 
safe therapeutic option.
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